首页> 外文期刊>Nature >p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation
【24h】

p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation

机译:p53和Pten控制神经和神经胶质瘤干/祖细胞的更新和分化

获取原文
获取原文并翻译 | 示例
       

摘要

Glioblastoma (GBM) is a highly lethal brain tumour presenting as one of two subtypes with distinct clinical histories and molecular profiles. The primary GBM subtype presents acutely as a high-grade disease that typically harbours mutations in EGFR, PTEN and INK4A/ARF (also known as CDKN2A), and the secondary GBM subtype evolves from the slow progression of a low-grade disease that classically possesses PDGF and TP53 events. Here we show that concomitant central nervous system (CNS)-specific deletion of p53 and Pten in the mouse CNS generates a penetrant acute-onset high-grade malignant glioma phenotype with notable clinical, pathological and molecular resemblance to primary GBM in humans. This genetic observation prompted TP53 and PTEN mutational analysis in human primary GBM, demonstrating unexpectedly frequent inactivating mutations of TP53 as well as the expected PTEN mutations. Integrated transcriptomic profiling, in silico promoter analysis and functional studies of murine neural stem cells (NSCs) established that dual, but not singular, inactiva-tion of p53 and Pten promotes an undifferentiated state with high renewal potential and drives increased Myc protein levels and its associated signature. Functional studies validated increased Myc activity as a potent contributor to the impaired differentiation and enhanced renewal of NSCs doubly null for p53 and Pten (p53~(-∕ -) Pten~(-∕ -)) as well as tumour neurospheres (TNSs) derived from this model. Myc also serves to maintain robust tumorigenic potential of p53~(-∕ -) Pten~(-∕ -) TNSs. These murine modelling studies, together with confirmatory transcriptomic/promoter studies in human primary GBM, validate a pathogenetic role of a common tumour suppressor mutation profile in human primary GBM and establish Myc as an important target for cooperative actions of p53 and Pten in the regulation of normal and malignant stem/progenitor cell differentiation, self-renewal and tumorigenic potential.
机译:胶质母细胞瘤(GBM)是高度致死性脑肿瘤,表现为两种具有不同临床历史和分子谱的亚型之一。主要的GBM亚型急性表现为高级别疾病,通常具有EGFR,PTEN和INK4A / ARF(也称为CDKN2A)突变,而次要GBM亚型则由经典的低级别疾病的缓慢发展演变而来PDGF和TP53事件。在这里,我们显示小鼠CNS中伴随的中枢神经系统(CNS)特异性p53和Pten缺失产生了一种渗透性急性发作的高级别恶性神经胶质瘤表型,与人类原发性GBM的临床,病理和分子相似。这项遗传学观察提示了人类原发性GBM中的TP53和PTEN突变分析,证明了TP53的意外失活突变以及预期的PTEN突变。整合的转录组分析,计算机启动子分析和鼠神经干细胞(NSCs)的功能研究证实,p53和Pten的双重失活(非单一失活)可促进具有高更新潜力的未分化状态,并驱动Myc蛋白水平及其增高。相关签名。功能研究证实,增加的Myc活性是导致p53和Pten(p53〜(-∕-)Pten〜(-∕-))以及肿瘤神经球(TNSs)分化受损和NSCs增强双重无效的有效因素。从这个模型。 Myc还可以维持p53〜(-∕-)Pten〜(-∕-)TNS的强大致瘤潜力。这些鼠类模型研究与人类原发性GBM中的确证转录组/启动子研究一起,验证了人类原发性GBM中常见的抑癌基因突变谱的致病作用,并将Myc确立为p53和Pten协同调节B53的重要靶点。正常和恶性干/祖细胞分化,自我更新和致瘤潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号